Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegileridine fumarate versus sufentanil for perioperative safety and efficacy in hysteroscopic surgery
ChiCTR2600132640Phase 4Not yet recruiting
- Sponsor
- Hangzhou First People's Hospital
- Start
- Oct 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tegileridine and sufentanil (2 arms), sponsored by Hangzhou First People's Hospital. Primary endpoint: Incidence of intraoperative hypoxemia. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
tegileridinesufentanil
Beyond the preview
Go deeper on ChiCTR2600132640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132640.